NASDAQ:ELVN Enliven Therapeutics Q4 2025 Earnings Report $59.32 -0.33 (-0.55%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Enliven Therapeutics EPS ResultsActual EPS-$0.48Consensus EPS -$0.42Beat/MissMissed by -$0.06One Year Ago EPSN/AEnliven Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.01 millionBeat/MissN/AYoY Revenue GrowthN/AEnliven Therapeutics Announcement DetailsQuarterQ4 2025Date3/3/2026TimeBefore Market OpensConference Call DateTuesday, March 3, 2026Conference Call Time3:00PM ETUpcoming EarningsEnliven Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Enliven Therapeutics Earnings HeadlinesEnliven Therapeutics to Present at Upcoming Investor ConferencesSeptember 3 at 4:05 PM | prnewswire.comEnliven Therapeutics: A Clean Active-Site TKI Could Redefine CML SequencingSeptember 3 at 10:00 AM | seekingalpha.comU.K. Royal Air Force officer just cracked America’s biggest economic secretA former Royal Air Force officer who helped build the trading systems behind London's Big Bang says he's uncovered a 55 year, bipartisan U.S. monetary policy he calls Project Pyramid. Since it began, the dollar supply has grown 35 times over, while wages have failed to keep pace. He argues the only way to protect your money is to outgrow the devaluation itself.September 4 at 1:00 AM | Weiss Ratings (Ad)Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingAugust 31, 2026 | prnewswire.comEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 5, 2026 | prnewswire.comProfitable biotechs strut their stuff as stock market stumblesJuly 17, 2026 | msn.comSee More Enliven Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email. Email Address About Enliven TherapeuticsEnliven Therapeutics (NASDAQ:ELVN) is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors. The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies. Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment. View Enliven Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
